AI-Powered Research

Conditions: Refractory Mycosis Fungoides and Sezary Syndrome
Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7
Recurrent Mycosis Fungoides and Sezary Syndrome
Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2014-09-18

Last Posted Date: 2019-09-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT02243579

Locations: 🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 5 locations

Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment

Active, not recruiting

Conditions: Malignant Neoplasm

Interventions: Other: Laboratory Biomarker Analysis

First Posted Date: 2014-09-18

Last Posted Date: 2025-04-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 170

Registration Number: NCT02243592

Locations: 🇺🇸
Henry Ford Health Providence Southfield Hospital, Southfield, Michigan, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Kaiser Permanente-Fresno, Fresno, California, United States

and more 70 locations

Iloprost in Preventing Lung Cancer in Former Smokers

Phase 1

Completed

Conditions: Lung Carcinoma

Interventions: Other: Placebo Administration
Drug: Iloprost
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2014-09-11

Last Posted Date: 2023-11-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT02237183

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸
UCHealth University of Colorado Hospital, Aurora, Colorado, United States

Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors

Completed

Conditions: Thymic Cancer
Prostate Cancer
Lung Cancer
Bladder Cancer

Interventions: Behavioral: Participant interview

First Posted Date: 2014-09-09

Last Posted Date: 2016-09-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT02233842

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Phase 1

Withdrawn

Conditions: Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease
Primary Effusion Lymphoma

Interventions: Drug: Pomalidomide
Drug: Rituximab
Drug: Prednisone
Drug: Etoposide
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide

First Posted Date: 2014-08-29

Last Posted Date: 2018-08-31

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT02228512

Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1

Completed

Conditions: Adult Gliosarcoma
Adult Giant Cell Glioblastoma
Adult Glioblastoma

Interventions: Drug: Tipifarnib
Radiation: External Beam Radiation Therapy
Drug: Temozolomide
Other: Laboratory Biomarker Analysis

First Posted Date: 2014-08-28

Last Posted Date: 2014-12-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT02227901

Locations: 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

Comparison of Two Dose Assessment Methods for Exposures to Nuclear Detonation Radiation

Completed

Conditions: Radiation Exposure

First Posted Date: 2014-08-27

Last Posted Date: 2019-12-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT02226874

Locations: 🇺🇸
Colorado State University, Fort Collins, Colorado, United States

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Phase 3

Active, not recruiting

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8
Recurrent Melanoma
Clinical Stage IV Cutaneous Melanoma AJCC v8
Metastatic Melanoma
Unresectable Melanoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Dabrafenib Mesylate
Procedure: Echocardiography Test
Biological: Ipilimumab
Procedure: Multigated Acquisition Scan
Biological: Nivolumab
Other: Quality-of-Life Assessment
Drug: Trametinib Dimethyl Sulfoxide

First Posted Date: 2014-08-25

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 300

Registration Number: NCT02224781

Locations: 🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸
Emory Decatur Hospital, Decatur, Georgia, United States
🇺🇸
CTCA at Western Regional Medical Center, Goodyear, Arizona, United States

and more 837 locations

Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1

Completed

Conditions: CD20 Positive
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Drug: Ibrutinib
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Biological: Rituximab